PAB

14.3%

0.6¢

PATRYS LIMITED

Market Cap $12.34M Add to my watchlist

Healthcare Biotechnology

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

PAB

Ann: PAT-DX1 GMP specification testing update

18:18

16K

18:18

Last post Raffout

16K

PAB

Ann: Further update on PAT-DX1 GMP manufacturing run

28/08/24

103

30K

28/08/24

Last post Travis Cloke

103

30K

PAB

Ann: Appendix 4E and 2024 Annual Report

24/08/24

1.6K

24/08/24

Last post Thejerry01

1.6K

PAB

Ann: Appendix 4G and Corporate Governance Statement

23/08/24

297

23/08/24

Last post

ASX News

297

PAB

Ann: Update on GMP manufacturing run of PAT-DX1

27/07/24

6.8K

27/07/24

Last post gassed

6.8K

PAB

Ann: Appendix 4C - Quarterly - 30 June 2024

26/07/24

4.9K

26/07/24

Last post orion123

4.9K

PAB

M & A Activities

22/07/24

5.4K

22/07/24

Last post Outgoing123

5.4K

PAB

Ann: Positive preclinical data for deoxymabs in vasculitis

28/06/24

24K

28/06/24

Last post Ajjax

24K

See All Discussions

Timeline

PAT-DX1 GMP specification testing update
29 Aug 09:15	Share

Appendix 4G and Corporate Governance Statement
23 Aug 17:31	Share

Appendix 4E and 2024 Annual Report
23 Aug 17:25	Share

Further update on PAT-DX1 GMP manufacturing run
29 Jul 09:31	Share

Appendix 4C - Quarterly - 30 June 2024
23 Jul 09:40	Share

Update on GMP manufacturing run of PAT-DX1
01 Jul 09:03	Share

Appendix 4C - Quarterly - 31 March 2024
30 Apr 09:20	Share

Positive preclinical data for deoxymabs in vasculitis
09 Apr 09:31	Share

Change of Director's Interest Notice
22 Mar 09:53	Share

Notification of cessation of securities - PAB
22 Mar 09:48	Share

Presentation to highlight broader potential of Deoxymabs
04 Mar 10:06	Share

Appendix 4D - Half Year Accounts - 31 December 2023
23 Feb 14:51	Share

Appendix 4C - Quarterly - 31 December 2023
23 Jan 09:52	Share

Change of Director's Interest Notice
22 Dec 10:56	Share

GMP Production of PAT-DX1 Next Quarter
13 Dec 09:21	Share

Change of Director's Interest Notices x2
29 Nov 13:48	Share

Notification of cessation of securities - PAB
29 Nov 13:42	Share

Amended Constitution
15 Nov 17:06	Share

Results of Annual General Meeting
15 Nov 17:00	Share

Chair's Address and CEO Presentation to 2023 AGM
15 Nov 11:05	Share

Notification of Expiry of PABOA Listed Options
13 Nov 09:42	Share

Patrys Receives R&D Tax Incentive Refund
08 Nov 11:50	Share

Appendix 4C - Quarterly - 30 September 2023
20 Oct 09:45	Share

Data to be presented at leading brain cancer conference
19 Oct 09:40	Share

Notice of Annual General Meeting/Proxy Form
12 Oct 15:00	Share

Final Director's Interest Notice
20 Sep 17:45	Share

View More

(20min delay)
Last 0.6¢		Change -0.001(14.3%)		Mkt cap ! $12.34M

Open	High	Low	Value	Volume
0.6¢	0.6¢	0.6¢	$4.623K	770.5K

Buyers (Bids)

No.	Vol.	Price($)
6	3244344	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	2325084	5

View Market Depth

No.	Vol.	Price($)
6	3244344	0.006
14	6170824	0.005
8	5414000	0.004
6	6065682	0.003
2	2770000	0.002

Price($)	Vol.	No.
0.007	2325084	5
0.008	1521890	4
0.009	955280	2
0.010	981860	4
0.011	80000	1

Last trade - 16.10pm 19/09/2024 (20 minute delay)


Last 0.6¢		Change -0.001 ( 0.00 %)
Open	High	Low	Volume
0.6¢	0.7¢	0.6¢	825000
Last updated 12.23pm 19/09/2024 ?

PAB (ASX) Chart

PATRYS LIMITED

Corporate Spotlight
Not Yet Available

Latest Threads

Second round assay results shapes promising greenfields gold discovery at Claw Gold Project

Timeline

Featured News

Latest Videos

Patrys (ASX:PAB) flags "synthetic lethality" potential of PAT-DX3 cancer treatment

14 Mar 2023 14:42 (AEDT)

Patrys (ASX:PAB) receives $3.35m R&D tax incentive refund

30 Jan 2023 14:37 (AEDT)

Latest Articles

Patrys (ASX:PAB) shares tumble as PAT-DX1 cancer treatment trial gets pushed back

Patrys (ASX:PAB) has flagged delays to the phase one clinical trial of its PAT-DX1 compound after a "sporadic issue" was raised by its contract development manufacturing organisation (CDMO).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

PATRYS LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Second round assay results shapes promising greenfields gold discovery at Claw Gold Project

Timeline

Featured News

Latest Videos

Patrys (ASX:PAB) flags "synthetic lethality" potential of PAT-DX3 cancer treatment

14 Mar 2023 14:42 (AEDT)

Patrys (ASX:PAB) receives $3.35m R&D tax incentive refund

30 Jan 2023 14:37 (AEDT)

Latest Articles

Patrys (ASX:PAB) shares tumble as PAT-DX1 cancer treatment trial gets pushed back

Patrys (ASX:PAB) has flagged delays to the phase one clinical trial of its PAT-DX1 compound after a "sporadic issue" was raised by its contract development manufacturing organisation (CDMO).

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News

Corporate Spotlight
Not Yet Available